Fezolinetant is an investigational nonhormonal treatment for vasomotor symptoms (VMS) associated with menopause More than half of women ages 40 to 64 wor...
Everest Medicines announced that its licensing partner, Pfizer Inc. (NYSE: PFE) has received approval from the U.S. Food and Drug Administratio...
Indivior PLC (LSE/Nasdaq: INDV), a leading addiction treatment company, today announced that it has gained exclusive global rights to develop, manufacture,...
Hansa Biopharma, "Hansa", a pioneer in enzyme technology for rare immunological conditions, announced high-level results from NICE-01, the first-in-h...
According to Cytiva’s 2023 Global Biopharma Resilience Index, the manufacturing of biologics in India is likely to increase over the next three years...
TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United States FDA approval is based on a robust analytical, non...
The goal is to generate DNA-encoded library (DEL) screening data for large numbers of under-addressed proteins in the human proteome — ultimately all...
"The NDA approval of XERAVA® in Taiwan marks an important step towards bringing this novel, critical therapy for complicated intra-abdominal infections...
Evozyne announced the closing of an $81 million Series B investment round that will fund the biotech’s generative AI-powered drug discovery platform ...
Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, tod...
“We are thrilled to receive marketing approval for AVT04 in Japan, which will be Alvotech’s second marketed biosimilar,” said Robert Wess...
Subcutaneous EPKINLYTM (epcoritamab) is the first and only bispecific antibody approved in Japan to treat adult patients with certain types of relapsed/r...
Novo Nordisk licenses three preclinical drug discovery programmes in cardiovascular diseases discovered and developed by Valo using the Opal Computational ...
CBM brings extensive cell and gene therapy expertise to SK pharmteco portfolio and continues SK pharmteco’s strategy to deliver end-to-end, multi-mod...
© 2025 Biopharma Boardroom. All Rights Reserved.
